Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 4/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DTYMK | P23919 | 2/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
| ▸ | ADK | P55263 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19175313 | 0.89 | P2RX3 (0.44) | POLBDTYMK | |
| SCHEMBL20417775 | 0.89 | P2RX3 (0.44) | POLBDTYMK | |
| SCHEMBL18840558 | 0.87 | POLB (0.51) | POLBDTYMKENPP1 | |
| SCHEMBL18840575 | 0.85 | P2RY2 (0.40) | POLB | |
| SCHEMBL18844352 | 0.83 | POLB (0.49) | POLB | |
| SCHEMBL18855472 | 0.81 | POLB (0.51) | POLBENPP1 | |
| SCHEMBL18844356 | 0.80 | DUT (0.47) | — | |
| SCHEMBL18840495 | 0.76 | P2RX3 (0.58) | POLBDTYMKENPP1 | |
| SCHEMBL18844349 | 0.76 | P2RX3 (0.58) | POLBDTYMKENPP1 | |
| SCHEMBL21191418 | 0.76 | CA2 (0.36) | POLBDTYMK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137869-A1 | METHODS FOR SYNTHESIZING NUCLEOTIDE ANALOGUES WITH DISULFIDE LINKERS | IsoPlexis Corporation | 2017-05-18 | — | — | US | disclosed |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | IsoPlexis Corporation | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137869-A1 | METHODS FOR SYNTHESIZING NUCLEOTIDE ANALOGUES WITH DISULFIDE LINKERS | RNGTT, NT5C3B, DUT | PRMT5 2324/4885METTL3 135/4885WDR77 692/4885 |
| US-20170130051-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | PRMT5 1932/4885METTL3 60/4885WDR77 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.